Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Abstract Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an immune checkpoint inhibitor, but lack of comprehensive analyses. In this...

Full description

Bibliographic Details
Main Authors: Feng Wang, Shukui Qin, Xinchen Sun, Zhenggang Ren, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang, Ping Yan, Jianjun Zou
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Journal of Hematology & Oncology
Subjects:
Anti–PD-1 antibody
Camrelizumab
Reactive cutaneous capillary endothelial proliferation
Hepatocellular carcinoma
Immune-related adverse events
Online Access:http://link.springer.com/article/10.1186/s13045-020-00886-2

Internet

http://link.springer.com/article/10.1186/s13045-020-00886-2

Similar Items